Drug war: Trump takes on big pharma
Economist Podcasts
00:00
Navigating Drug Pricing Disruptions
This chapter explores the recent turmoil in the pharmaceutical sector triggered by government actions aimed at lowering drug prices in America. It highlights the concerns of industry executives about potential consequences on costs, supply chains, and new medication approvals while examining the challenges of pricing transparency. Additionally, the chapter addresses the implications of tariffs on pharmaceutical companies, emphasizing the delicate balance between profitability, accessibility, and the future of drug innovation.
Transcript
Play full episode
